摘要: The FDA approved 41 new therapeutics in 2014, but the bumper year fell short of commercial power drugs 2013.
nature.com
fsk.it参考文章(5)
Asher Mullard, New checkpoint inhibitors ride the immunotherapy tsunami Nature Reviews Drug Discovery. ,vol. 12, pp. 489- 492 ,(2013) , 10.1038/NRD4066
Man Tsuey Tse, All-oral HCV therapies near approval. Nature Reviews Drug Discovery. ,vol. 12, pp. 409- 411 ,(2013) , 10.1038/NRD4036
Asher Mullard, Momentum builds around new antibiotic business models Nature Reviews Drug Discovery. ,vol. 13, pp. 711- 713 ,(2014) , 10.1038/NRD4455
Asher Mullard, Breakthrough programme turns two Nature Reviews Drug Discovery. ,vol. 13, pp. 873- 875 ,(2014) , 10.1038/NRD4487
Asher Mullard, 2013 FDA drug approvals. Nature Reviews Drug Discovery. ,vol. 13, pp. 85- 89 ,(2014) , 10.1038/NRD4239